Repository logo
Log in(current)
Repository logoMIT Open ScholarshipDSpace@MIT
  1. Home
  2. MIT Open Access Articles
  3. MIT Open Access Articles
  4. Toward Fulfilling the Promise of Molecular Medicine in Fragile X

Toward Fulfilling the Promise of Molecular Medicine in Fragile X

Thumbnail Image
Download
Name

Bear-Toward Fulfilling.pdf

Size

436.59 KB

Format

Adobe PDF

Checksum (MD5)

b30ec8bcfa18a2ca06d9a419c845d559

Author(s)
Krueger, Dilja
•
Bear, Mark
Date Issued
February 2011
Journal
Annual Review of Medicine
Publisher
Annual Reviews
Citation
Krueger, Dilja D., and Mark F. Bear. “Toward Fulfilling the Promise of Molecular Medicine in Fragile X Syndrome.” Annual Review of Medicine 62.1 (2011): 411–429.
Version
Author's final manuscript
Abstract
Fragile X syndrome (FXS) is the most common inherited form of mental retardation and a leading known cause of autism. It is caused by loss of expression of the fragile X mental retardation protein (FMRP), an RNA-binding protein that negatively regulates protein synthesis. In neurons, multiple lines of evidence suggest that protein synthesis at synapses is triggered by activation of group 1 metabotropic glutamate receptors (Gp1 mGluRs) and that many functional consequences of activating these receptors are altered in the absence of FMRP. These observations have led to the theory that exaggerated protein synthesis downstream of Gp1 mGluRs is a core pathogenic mechanism in FXS. This excess can be corrected by reducing signaling by Gp1 mGluRs, and numerous studies have shown that inhibition of mGluR5, in particular, can ameliorate multiple mutant phenotypes in animal models of FXS. Clinical trials based on this therapeutic strategy are currently under way. FXS is therefore poised to be the first neurobehavioral disorder in which corrective treatments have been developed from the bottom up: from gene identification to pathophysiology in animals to novel therapeutics in humans. The insights gained from FXS and other autism-related single-gene disorders may also assist in identifying molecular mechanisms and potential treatment approaches for idiopathic autism.
MIT Department
Massachusetts Institute of Technology. Department of Brain and Cognitive Sciences
Picower Institute for Learning and Memory
Terms of Use
Creative Commons Attribution-Noncommercial-Share Alike 3.0
http://creativecommons.org/licenses/by-nc-sa/3.0/
Persistent DSpace Link
http://hdl.handle.net/1721.1/69161
DOI of Published Version
https://doi.org/10.1146/annurev-med-061109-134644
Repository logo
PrivacyPermissionsAccessibilityContact us
Repository logo
Notify us about copyright concerns.